Related Experiment Video
Updated: May 27, 2026
Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues
Published on: June 2, 2023
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network
Claudia Zierold1, Marjorie A Carlson, Udo C Obodo
1University of Minnesota School of Medicine, Minneapolis, USA.
Insights
Bone marrow mononuclear cells show moderate cardiac benefits in cardiovascular disease patients. Further research is needed to understand the mechanisms and develop biomarkers for effective cell therapy.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Biotechnology
Background:
- Bone marrow mononuclear cell therapy shows potential for improving cardiac performance in cardiovascular disease.
- Current understanding of the underlying mechanisms driving these improvements remains limited.
- A need exists for robust research infrastructure to investigate cell therapy efficacy.
Purpose of the Study:
- To establish a comprehensive biorepository for bone marrow and peripheral blood samples.
- To conduct extensive phenotyping and cell function studies.
- To correlate cell characteristics with clinical outcomes for biomarker development.
Main Methods:
- Establishment of the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Cell Therapy Research Network (CCTRN) Biorepository Core.
- Long-term storage (10 years) of bone marrow and peripheral blood.
- Analysis of cell populations and functions alongside clinical data and outcomes.
Main Results:
- The biorepository facilitates detailed analysis of cell therapy components.
- Linking cell properties to clinical outcomes is crucial for understanding treatment effects.
- Data generated supports the identification of potential diagnostic and prognostic markers.
Conclusions:
- Understanding the mechanisms of cell therapy is essential for optimizing cardiovascular treatments.
- The CCTRN Biorepository is vital for advancing cell therapy research.
- Development of biomarkers will define the safety and efficacy of future cell-based therapies.
Abstract:
Moderate improvements in cardiac performance have been reported in some clinical settings after delivery of bone marrow mononuclear cells to patients with cardiovascular disease. However, mechanistic insights into how these cells impact outcomes are lacking. To address this, the National Heart, Lung and Blood Institute (NHLBI) Cardiovascular Cell Therapy Research Network (CCTRN) established a Biorepository Core for extensive phenotyping and cell function studies and storing bone marrow and peripheral blood for 10 years. Analyzing cell populations and cell function in the context of clinical parameters and clinical outcomes after cell or placebo treatment empower the development of novel diagnostic and prognostics. Developing such biomarkers that define the safety and efficacy of cell therapy is a major Biorepository aim.
